Barclays PLC Veracyte, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Barclays PLC holds 146,402 shares of VCYT stock, worth $6.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146,402
Previous 146,402 -0.0%
Holding current value
$6.03 Million
Previous $4.98 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$21.0 - $35.25 $1.79 Million - $3 Million
85,033 Added 138.56%
146,402 $4.98 Million
Q2 2024

Aug 14, 2024
SELL
$18.86 - $23.55 $522,591 - $652,546
-27,709 Reduced 31.11%
61,369 $1.33 Million
Q1 2024

May 15, 2024
SELL
$21.0 - $29.1 $1.83 Million - $2.54 Million
-87,312 Reduced 49.5%
89,078 $1.98 Million
Q4 2023

Feb 15, 2024
BUY
$19.72 - $28.68 $855,433 - $1.24 Million
43,379 Added 32.61%
176,390 $4.85 Million
Q3 2023

Nov 07, 2023
SELL
$22.33 - $29.92 $987,186 - $1.32 Million
-44,209 Reduced 24.95%
133,011 $2.97 Million
Q2 2023

Aug 03, 2023
BUY
$20.96 - $26.99 $660,596 - $850,643
31,517 Added 21.63%
177,220 $4.51 Million
Q1 2023

May 04, 2023
SELL
$20.58 - $27.89 $615,259 - $833,799
-29,896 Reduced 17.03%
145,703 $3.25 Million
Q4 2022

Feb 13, 2023
SELL
$15.31 - $29.94 $781,437 - $1.53 Million
-51,041 Reduced 22.52%
175,599 $4.17 Million
Q3 2022

Nov 03, 2022
BUY
$16.58 - $27.9 $3.3 Million - $5.55 Million
198,779 Added 713.47%
226,640 $3.76 Million
Q2 2022

Aug 12, 2022
SELL
$15.45 - $29.52 $86,983 - $166,197
-5,630 Reduced 16.81%
27,861 $555,000
Q1 2022

May 16, 2022
SELL
$21.94 - $42.51 $1.33 Million - $2.58 Million
-60,625 Reduced 64.42%
33,491 $924,000
Q4 2021

Feb 14, 2022
SELL
$36.09 - $53.79 $2.51 Million - $3.73 Million
-69,435 Reduced 42.45%
94,116 $3.88 Million
Q3 2021

Nov 09, 2021
BUY
$35.62 - $52.97 $4.99 Million - $7.43 Million
140,186 Added 599.98%
163,551 $7.6 Million
Q2 2021

Aug 13, 2021
SELL
$32.94 - $56.62 $1.37 Million - $2.35 Million
-41,447 Reduced 63.95%
23,365 $934,000
Q1 2021

May 13, 2021
SELL
$44.47 - $81.38 $1.72 Million - $3.15 Million
-38,678 Reduced 37.37%
64,812 $3.48 Million
Q4 2020

Feb 11, 2021
SELL
$32.49 - $61.88 $378,443 - $720,778
-11,648 Reduced 10.12%
103,490 $5.07 Million
Q3 2020

Nov 12, 2020
BUY
$26.73 - $35.67 $1.44 Million - $1.92 Million
53,953 Added 88.18%
115,138 $3.74 Million
Q2 2020

Aug 12, 2020
BUY
$19.49 - $28.11 $230,293 - $332,147
11,816 Added 23.93%
61,185 $1.59 Million
Q1 2020

May 13, 2020
SELL
$16.13 - $30.17 $13,113 - $24,528
-813 Reduced 1.62%
49,369 $1.2 Million
Q4 2019

Feb 10, 2020
BUY
$20.78 - $29.99 $345,987 - $499,333
16,650 Added 49.65%
50,182 $1.4 Million
Q3 2019

Nov 14, 2019
SELL
$23.87 - $30.93 $378,387 - $490,302
-15,852 Reduced 32.1%
33,532 $805,000
Q2 2019

Aug 14, 2019
BUY
$22.1 - $28.56 $634,004 - $819,329
28,688 Added 138.62%
49,384 $1.41 Million
Q1 2019

May 15, 2019
BUY
$12.0 - $25.76 $94,008 - $201,803
7,834 Added 60.91%
20,696 $518,000
Q4 2018

Feb 14, 2019
SELL
$9.15 - $14.85 $118,748 - $192,723
-12,978 Reduced 50.22%
12,862 $162,000
Q3 2018

Nov 14, 2018
BUY
$9.55 - $12.64 $221,197 - $292,767
23,162 Added 864.9%
25,840 $247,000
Q2 2018

Aug 14, 2018
SELL
$5.39 - $9.66 $14,434 - $25,869
-2,678 Reduced 50.0%
2,678 $24,000
Q1 2018

May 15, 2018
BUY
$5.44 - $6.97 $8,693 - $11,138
1,598 Added 42.52%
5,356 $29,000
Q4 2017

Feb 14, 2018
BUY
$6.05 - $9.37 $18,422 - $28,531
3,045 Added 427.07%
3,758 $25,000
Q3 2017

Nov 14, 2017
BUY
$7.81 - $8.77 $5,568 - $6,253
713
713 $6,000

Others Institutions Holding VCYT

# of Institutions
307
Shares Held
81.7M
Call Options Held
134K
Put Options Held
13.3K
View Full List

About VERACYTE, INC.

VCYT Quotes by TradingView
  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.95B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email